Key result
Azelnidipine enhanced the amelioration of vascular endothelial dysfunction and remodeling by olmesartan to a greater extent than did hydrochlorothiazide in salt-loaded hypertensive rats.
Why the study?
Does the combination of an ARB and a CCB improve vascular protection more than an ARB and a diuretic in salt-loaded hypertensive rats?
Does the combination of an ARB and a CCB improve vascular protection more than an ARB and a diuretic in salt-loaded hypertensive rats?
In salt-loaded hypertensive rats, combining an ARB with a CCB provides greater vascular protection than combining an ARB with a diuretic, despite similar blood pressure reductions.
Answers are grounded in this paper and cite their sources.
Should not yet change antihypertensive regimens in practice; leaves open whether ARB-CCB combinations confer superior vascular protection in humans.
The combination therapy of an angiotensin receptor blocker (ARB) with a calcium channel blocker (CCB) or with a diuretic is favorably recommended for the treatment of hypertension. However, the difference between these two combination therapies is unclear. The present work was undertaken to examine the possible difference between the two combination therapies in vascular protection. Salt-loaded stroke-prone spontaneously hypertensive rats (SHRSP) were divided into 6 groups, and they were orally administered (1) vehicle, (2) olmesartan, an ARB, (3) azelnidipine, a CCB, (4) hydrochlorothiazide, a diuretic, (5) olmesartan combined with azelnidipine, or (6) olmesartan combined with hydrochlorothiazide. Olmesartan combined with either azelnidipine or hydrochlorothiazide ameliorated vascular endothelial dysfunction and remodeling in SHRSP more than did monotherapy with either agent. However, despite a comparable blood pressure lowering effect between the two treatments, azelnidipine enhanced the amelioration of vascular endothelial dysfunction and remodeling by olmesartan to a greater extent than did hydrochlorothiazide in salt-loaded SHRSP. The increased enhancement by azelnidipine of olmesartan-induced vascular protection than by hydrochlorothiazide was associated with a greater amelioration of vascular nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation, superoxide, mitogen-activated protein kinase activation, and with a greater activation of the Akt/endothelial nitric oxide synthase (eNOS) pathway. These results provided the first evidence that a CCB potentiates the vascular protective effects of an ARB in salt-sensitive hypertension, compared with a diuretic, and provided a novel rationale explaining the benefit of the combination therapy with an ARB and a CCB.
No takes yet. Share an insight, caveat, or question.
Yamamoto et al. (2012) studied Salt-loaded hypertension (n=48). Olmesartan combined with azelnidipine vs. Olmesartan 1 mg/kg/day + hydrochlorothiazide 5 mg/kg/day was evaluated on Vascular endothelial function (acetylcholine-induced vascular endothelium-dependent relaxation) (p=<0.01). Azelnidipine enhanced the amelioration of vascular endothelial dysfunction and remodeling by olmesartan to a greater extent than did hydrochlorothiazide in salt-loaded hypertensive rats.
Synapse has enriched 10 related papers. Consider them for comparative context: